Program
nitrosomonas eutropha D23
Also written as “B244”, “Experimental: B244” and “B244 suspension”.
Its studies are mostly in Acne Vulgaris · Dermatitis, Atopic · Eczema · Rhinitis, Allergic · Migraine Disorders, led by AOBiome.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AOBiome | 101 open or running | phase 3since Jul 8, 2016 | Jan 11, 2016 | Aug 2027phase 2 · NCT07866105 |
Also a collaborator on its studies: biorasi-llc and integrium.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 11, 2016First study: phase 2 study in Acne VulgarisFirst studyNCT02656485 · 36 enrolled · United States
- Jul 8, 2016Phase 3 study in Acne VulgarisNCT02832063 · 372 enrolled · United States
- Nov 22, 2016Phase 2 study in PrehypertensionNCT02998840 · 132 enrolled · United States
- Jul 20, 2017Phase 2 study in Atopic Dermatitis EczemaNCT03235024 · 122 enrolled · United States
- Sep 15, 2017Phase 2 study in Rhinitis, AllergicNCT03290248 · 71 enrolled · United States, Canada
- Mar 26, 2018Phase 2 study in Migraine DisordersNCT03488563 · 313 enrolled · United States
- Jun 25, 2018Phase 2 study in RosaceaNCT03590366 · 140 enrolled · United States
- Dec 7, 2018Phase 1 study in EczemaNCT03775434 · 28 enrolled · United States
- Jul 16, 2020Phase 2 study in Dermatitis, AtopicNCT04490109 · 547 enrolled · United States
- Oct 5, 2026Phase 2 study in Acne VulgarisNCT07866105 · 176 planned
Ahead
- Aug 2027Primary completion: phase 2 study in Acne VulgarisNCT07866105
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 10 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07866105Acne Vulgaris | 2 | Not yet recruiting | Aug 2027 | 176 |
| NCT04490109Dermatitis, Atopic · United States | 2 | Completed | Dec 10, 2021 | 547 |
| NCT03775434Eczema · United States | 1 | Completed | May 18, 2019 | 28 |
| NCT03590366Rosacea · United States | 2 | Completed | Feb 11, 2019 | 140 |
| NCT03488563Migraine Disorders · United States | 2 | Completed | Jun 17, 2019 | 313 |
| NCT03290248Rhinitis, Allergic · United States, Canada | 2 | Completed | Dec 21, 2018 | 71 |
| NCT03235024Atopic Dermatitis Eczema · United States | 2 | Completed | Feb 27, 2019 | 122 |
| NCT02998840Prehypertension · United States | 2 | Completed | Apr 25, 2017 | 132 |
| NCT02832063Acne Vulgaris · United States | 3 | Completed | Jul 19, 2017 | 372 |
| NCT02656485Acne Vulgaris · United States | 2 | Completed | Mar 1, 2016 | 36 |
How it is read
Names in the registry
- “B244”, 8 entries
- “Experimental: B244”, 1 entry
- “B244 suspension”, 1 entry
Conditions, from the studies’ own filings
- Acne Vulgaris, 3 studies
- Dermatitis, Atopic, 2 studies
- Eczema, 1 study
- Rhinitis, Allergic, 1 study
- Migraine Disorders, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.